The Absolute Effect / Evidence / Bladder Cancer
GemX
Clinical question: Can weekly low-dose gemcitabine with four-week hypofractionated conformal radiotherapy achieve a high complete response and bladder preservation rate in selected MIBC?
Registry: No registry identifier reported in primary publication · One underlying study; aliases and related publications consolidated.
Prospective phase II · single arm · Evidence cut-off: 8 November 2026
Design, population and eligibility
Prospective, single-arm phase II study of weekly gemcitabine with four-week hypofractionated conformal radiotherapy after TURBT; no randomized comparator.
50 patients with muscle-invasive transitional-cell carcinoma; post-treatment cystoscopy available in 47.
T2–3 N0 M0 muscle-invasive bladder cancer after transurethral resection and MRI staging. Patient selection and bladder-preservation suitability are critical; this is not evidence for node-positive or metastatic disease.
Median follow-up 36 months (range 15–62 months).
Treatment and comparator
Intervention: Gemcitabine 100 mg/m² IV on days 1, 8, 15 and 22 with 52.5 Gy in 20 fractions over 4 weeks. Chemotherapy was stopped for RTOG grade 3 bladder or bowel toxicity.
Comparator: None; single-arm phase II study. No randomized comparison with 5-FU/mitomycin C, cisplatin or other radiosensitizers.
Primary endpoint: Tumour response, toxicity and survival.
Key outcomes
Complete endoscopic response: 44/50 (88%) 47 underwent post-treatment cystoscopy; the publication reports 44 (88%) of all enrolled.
Three-year cancer-specific survival: 82% Kaplan–Meier estimate.
Three-year overall survival: 75% Kaplan–Meier estimate.
Functional intact bladder among survivors: 32 of 36 alive patients Observed status at median 36-month follow-up.
Cystectomy: 4 patients Three for recurrent disease; one for toxicity.
GemX produced an 88% reported complete endoscopic response and 3-year CSS/OS estimates of 82%/75%. These are single-arm outcomes and cannot establish superiority over other radiosensitizing regimens.
Absolute outcome visualization
Single-arm complete endoscopic response and three-year survival estimates.
Values are reported at the stated time horizon; no outcome is derived from median survival. Single-arm data are not comparative effects.
NNT / NNH
Not applicable: no randomized comparator and no causal absolute benefit can be calculated. Do not compare the single-arm response rate directly with response rates from different trials.
Not applicable as a comparative NNH. Toxicity was managed with a protocol stopping rule; grade-specific incidence cannot be reconstructed from the abstract.
Toxicity, grade 3–5 harms and treatment burden
All 50 completed RT. Two patients stopped gemcitabine after two cycles and two after three cycles because of bowel toxicity; 46 tolerated all four cycles. Two treatment-associated deaths were reported. One patient required bowel resection for late toxicity. The primary abstract does not provide a complete grade 3–5 toxicity table; the grade 3 stopping rule is not itself an incidence estimate.
Four-week course: 20 RT fractions plus four weekly gemcitabine infusions. Chemotherapy interruption was allowed for RTOG grade 3 bladder/bowel toxicity. Four patients underwent subsequent cystectomy.
Quality of life
The original 50-patient report does not provide a formal longitudinal QoL result in the abstract. A separate 78-patient prospective tolerability cohort (including 38 patients after neoadjuvant chemotherapy) reported patient-reported LENT-SOMA scores; these data are related external cohort evidence and are not pooled with this trial.
Subgroups and applicability
The original cohort was T2–3 N0M0 transitional-cell carcinoma after TURBT. No validated subgroup effect is established. A later nonrandomized cohort examined GemX after neoadjuvant chemotherapy; it is not a randomized comparison.
Limitations
Small single-arm phase II; short median follow-up; no control arm; complete response denominator nuance; no robust comparative grade 3–5 safety estimates; two treatment-associated deaths; no formal comparative NNT/NNH. The 78-patient later tolerability cohort is separate and should not be counted as an additional GemX randomized study.
Clinical interpretation
GemX is a prospective phase II bladder-preservation regimen using gemcitabine 100 mg/m² weekly with 52.5 Gy/20 fractions. It demonstrated promising complete response and survival estimates, but the evidence is single-arm. It supports a radiosensitizing option for selected MIBC patients, not superiority over cisplatin or 5-FU/mitomycin C.
Contemporary-practice note (8 November 2026): Historical trial results are distinct from current practice. Comprehensive guideline-level freshness review remains pending for this batch; current guidance and MDT context should inform treatment selection.